FDA staff find small subset behind Inlyta effect (Reuters)

Reuters – Slower tumor growth in kidney cancer patients taking Pfizer Inc’s drug Inlyta in trial was driven by a small subset of patients who are likely rare in the United States, Food and Drug Administration researchers said.